Pfizer's Ticovac Receives the US FDA's Approval for the Prevention of Tick-Borne Encephalitis
Shots:
- The US FDA has approved Ticovac for active immunization to prevent TBE in patients aged ≥1 yrs. The US CDC's will discuss recommendations regarding the safe and appropriate use of the vaccine
- In clinical trials- safety & immunogenicity of Ticovac were evaluated across two age groups (aged 1-15 yrs. and >16 yrs.). The studies showed seropositivity rates (99.5% & 98.7-100%) following 3 doses respectively while the vaccine was generally well-tolerated with no unexpected AEs or vaccine-related serious AEs observed
- Additionally- real-world studies demonstrated that the vaccine is 96-98.7% effective in people who have received at least 3 doses of the vaccine
| Ref: Pfizer | Image: The Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com